BeiGene, Ltd. (BGNE)
After hours:
| Previous Close | 187.78 |
| Open | 192.39 |
| Bid | 186.28 x 800 |
| Ask | 192.98 x 800 |
| Day's Range | 189.78 - 193.95 |
| 52 Week Range | 124.46 - 280.62 |
| Volume | |
| Avg. Volume | 231,357 |
| Market Cap | 20.517B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., September 19, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has approved TEVIMBRA® (tislelizumab) as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy. Additionally, the U.S. Food and Drug Administration (FDA) accepted for
- Business Wire
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., September 19, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab).
- Business Wire
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., August 31, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11th, 2023 with a fireside chat at 9:20 am ET.
